 "Zydus Cadila gets tentative USFDA approval to market arthritis drug")
Don't want to miss the best from Business Standard?
Drug firm Zydus Cadila on Saturday said it has received a tentative approval from the US health regulator to market generic Apremilast tablets.
The company has received the tentative approval from the United States Food and Drug Administration (USFDA) to market the tablets in the strengths of 10 mg, 20 mg, and 30 mg, Zydus Cadila said in a filing to BSE.
This medication is used to treat psoriatic arthritis and moderate to severe plaque psoriasis. It is also used to treat mouth sores in people who have Behcet's disease, it added.
The tablets will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad, Zydus Cadila said.
The group now has 276 approvals and has so far filed over 360 ANDAs since the commencement of its filing process, it added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app